Survey of Oncology Nurses Reveals Knowledge Gaps Surrounding Biosimilars

A biosimilar is a biological agent that is very much like another previously FDA-approved biological agent, called the reference drug. Biosimilars and their reference drugs are both made from living organisms, but they may be made in different ways and of slightly different substances. A biosimilar must demonstrate the same safety and efficacy and work in the same way as the reference drug, and it must also be used in the same way, at the same dose, and for the same condition. There are currentl...
Continue reading

Survey of Oncology Nurses Reveals Knowledge Gaps Regarding PARP Inhibitor Therapies

Poly(ADP)-ribose polymerase (PARP) inhibition is a new form of targeted therapy that has exhibited effectiveness in treating several solid tumor types. Olaparib (Lynparza®, AstraZeneca), rucaparib (Rubraca®, Clovis Oncology), and niraparib (Zejula®, Tesaro) have all been approved for the treatment of advanced ovarian cancer. Olaparib has also been approved to treat BRCA-mutated breast cancer and is currently being investigated in the treatment of prostate cancer. Another PARP inhibitor, talazopa...
Continue reading

CAR T-Cell Therapies: Survey of Oncology Nurses Reveals Much to Be Learned

​ Chimeric antigen receptor (CAR) T-cell therapy is a form of immunotherapy in which a patient's own T cells are collected and genetically altered to target cancer cells. Although CAR T-cell therapies have shown encouraging results in patients with acute lymphoblastic leukemia and B-cell lymphomas, they are associated with several serious adverse events, including cytokine release syndrome, neurotoxicity, tumor lysis syndrome, and graft-versus-host disease.  In light of the growing use of C...
Continue reading

Scalp Cooling for Oncology Patients With Kerry Kluska, RN, MSN, OCN®

​ For patients with cancer, body image issues related to chemotherapy-induced hair loss can add to the stress of coping with their illness. To address this concern and help patients maintain their hair during chemotherapy, Lehigh Valley Health Network's Cancer Institute implemented a scalp cooling program. In this interview with i3 Health, Kerry Kluska, RN, MSN, OCN®, who served as a nurse and patient educator during the scalp cooling implementation, discusses the process involved in instituting...
Continue reading

Biosimilars in Oncology: An Interview With Eric Zack, DNP, RN, ACNP-BC, AOCN®, BMTCN®

Biosimilars—a biologic that is "similar" to another biologic drug that is already FDA approved—are becoming more common to prescribe to patients with various conditions. It is crucial for health care providers to keep abreast of the current information regarding biosimilars. To help educate oncology nurses on this emerging field, Eric Zack, DNP, RN, ACNP-BC, AOCN®, BMTCN® and colleagues created an intervention including an overview of the history of biosimilars and information about the biosimil...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.